Oncology Market Global Report 2025: Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape
Innovations in immunotherapies and personalized medicine, along with increased healthcare investments, are reshaping cancer care. The U.S. market stands out with a projected USD 377.1 billion valuation by 2034, thanks to robust R&D and government support, enhancing treatment accessibility and precision oncology adoption.
Oncology Market
Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Oncology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Oncology Market was valued at USD 320.3 billion in 2024, and is projected to reach USD 866.1 billion by 2034, rising at a CAGR of 10.8%.
The rising incidence of cancer worldwide remains the key driver of market expansion, prompting increased demand for advanced treatments and diagnostics. As cancer cases surge across all age groups, healthcare systems are intensifying efforts to improve patient outcomes through novel therapies, precision medicine, and technological advancements in diagnostics. The oncology sector continues to witness significant investment from pharmaceutical and biotechnology firms, leading to groundbreaking innovations in immunotherapies, targeted therapies, and early detection methods.
The growing focus on personalized medicine, driven by genomics and biomarker research, is transforming the landscape of cancer treatment. Government initiatives, rising healthcare expenditures, and increased awareness campaigns further contribute to market growth, emphasizing the urgent need for better accessibility to cutting-edge cancer therapies and diagnostics.
The oncology market is categorized into two primary segments: cancer diagnostics and cancer treatment. The cancer treatment segment, valued at USD 174.8 billion in 2024, is anticipated to grow at a CAGR of 11.3% between 2025 and 2034. The expansion of this segment is attributed to an increasing number of cancer diagnoses and regulatory approvals for novel treatments. Recent breakthroughs, including CAR-T cell therapies and next-generation immunotherapies, are reshaping cancer care, offering patients enhanced survival rates and improved quality of life. As pharmaceutical companies accelerate research and development efforts, the pipeline for innovative oncology drugs continues to expand, providing new hope for patients battling various forms of cancer.Oncology encompasses several cancer types, including lung, prostate, breast, and colorectal cancers. In 2024, the breast cancer segment accounted for USD 63.2 billion, securing a 20% market share. The rising prevalence of breast cancer, coupled with advancements in diagnostic imaging, liquid biopsies, and targeted therapies, fuels the segment's rapid growth. Increased awareness campaigns and enhanced screening programs are enabling early detection, significantly improving treatment success rates. The growing adoption of artificial intelligence in diagnostics and precision medicine in breast cancer treatment is also driving market expansion, paving the way for more effective, patient-centric therapeutic solutions.U.S. Oncology Market is poised to reach USD 377.1 billion by 2034, positioning the country as a global leader in cancer research and treatment. The increasing cancer burden, combined with strong government support and robust investment from pharmaceutical and biotechnology companies, is accelerating innovation in the oncology sector. With a growing number of hospitals, research institutions, and healthcare providers focusing on developing next-generation diagnostic tools and therapies, the U.S. continues to spearhead advancements in cancer care.
The rising adoption of precision oncology, expansion of clinical trials, and continuous improvements in treatment accessibility further strengthen the market's trajectory, ensuring a steady demand for breakthrough cancer treatments and cutting-edge diagnostic technologies.Comprehensive Market Analysis and Forecast
Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
Competitive landscape with Porter's Five Forces and PESTEL analysis
Market size, segmentation, and regional forecasts
In-depth company profiles, business strategies, financial insights, and SWOT analysis
The companies featured in this Oncology market report include:
AbbVie
Amgen
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
GE HealthCare Technologies
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Novartis
Pfizer
F. Hoffmann-La Roche
Sanofi
Takeda Pharmaceutical Company Limited
Key Attributes:
Report Attribute
Details
No. of Pages
135
Forecast Period
2024 - 2034
Estimated Market Value (USD) in 2024
$320.3 Billion
Forecasted Market Value (USD) by 2034
$866.1 Billion
Compound Annual Growth Rate
10.8%
Regions Covered
Global
Key Topics Covered: Chapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Rising incidence of cancer globally3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness3.2.1.3 Growing number of diagnostic laboratories in developing countries3.2.1.4 Technological advancements in developed countries3.2.2 Industry pitfalls and challenges3.2.2.1 High capital investment coupled with high cost associated with diagnostic imaging system3.2.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners3.2.2.3 Dearth of well-skilled and trained oncologists and radiologists3.3 Growth potential analysis3.4 Regulatory landscape3.5 Technological landscape3.6 Future market trends3.7 Gap analysis3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Cancer Diagnostics and Treatment, 2021-2034 ($ Mn)5.1 Key trends5.2 Cancer diagnostics5.2.1 Tumor biomarkers test5.2.2 Imaging5.2.3 Biopsy5.2.4 Liquid biopsy5.2.5 Immunohistochemistry5.2.6 In situ hybridization5.3 Cancer treatment5.3.1 Chemotherapy5.3.2 Targeted therapy5.3.3 Immunotherapy5.3.4 Hormonal therapy5.3.5 Other cancer treatmentsChapter 6 Market Estimates and Forecast, by Cancer Type, 2021-2034 ($ Mn)6.1 Key trends6.2 Lung cancer6.3 Prostate cancer6.4 Colon and rectal cancer6.5 Gastric cancer6.6 Esophageal cancer6.7 Liver cancer6.8 Breast cancer6.9 Other cancer typesChapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)7.1 Key trends7.2 Hospitals7.3 Diagnostic laboratories7.4 Diagnostic imaging centers7.5 Academia7.6 Specialty clinics7.7 Other end useChapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)Chapter 9 Company Profiles9.1 AbbVie9.2 Amgen9.3 AstraZeneca9.4 Bristol-Myers Squibb Company9.5 Eli Lilly and Company9.6 GE HealthCare Technologies9.7 Gilead Sciences9.8 GlaxoSmithKline9.9 Johnson & Johnson9.10 Merck & Co9.11 Novartis9.12 Pfizer9.13 F. Hoffmann-La Roche9.14 Sanofi9.15 Takeda Pharmaceutical Company LimitedFor more information about this report visit https://www.researchandmarkets.com/r/qw2trp
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Oncology Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
Kenyan government has revealed plans to adopt the Danish F2 platform
By GlobeNewswire Published on June 6, 2025, 11:57 IST Press Release no. 03/2025 Kenyan government has revealed plans to adopt the Danish F2 platform Copenhagen, June 6, 2025 cBrain (NASDAQ: CBRAIN) is pleased to share that the Kenyan Ministry of Information, Communications, and the Digital Economy has revealed plans to roll out the F2 digital platform across all government departments, thereby transitioning into paperless working environments. The plans were shared with Kenyan media by Cabinet Secretary William Kabogo on June 4, following a high-level meeting with the Danish Ambassador to Kenya, Stephan Schønemann. The project is being implemented with support from the Danish government, and cBrain is proud to contribute its technology to this strategic collaboration. According to the Cabinet Secretary, the new digital platform will be fundamental in reinforcing transparency and accountability in the Kenyan public service. 'To ensure efficient service delivery, the government requires clear processes and decision-making that can be traced, transparent, accountable, and timely. This is fundamental to ensure every action is fully auditable,' he told the media. This comes two months after the Cabinet Secretary told the media that the Ministry was piloting a paperless system, aiming to eliminate bureaucracies that slow down service delivery. F2 is a commercial off-the-shelf (COTS) digital platform designed specifically for government use, developed in close collaboration with the Danish government. F2 serves as the digital backbone for Denmark's central administration and is actively used by the Danish ministries and more than 75 Danish government organizations. Internationally, the F2 COTS for government platform has been deployed by government authorities across five continents. Purpose-built to support public sector workflows, compliance, and documentation needs, F2 enables fast, scalable, and legally compliant digital operations across the public sector. Best regards Per Tejs Knudsen, CEO Inquiries regarding this Press Release may be directed to Ejvind Jørgensen, CFO & Head of Investor Relations, cBrain A/S, [email protected], +45 2594 4973 Attachment Press Release no 2025-03 (Kenyan government has revealed plans to adopt F2) Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
28 minutes ago
- Yahoo
Burning Rock Reports First Quarter 2025 Financial Results
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the 'Company' or 'Burning Rock'), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma（OSCC）treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, double-blind phase 2 study, comparing the efficacy of systemic treatment combining nCT with immunotherapy against nCT alone for OSCC patients. The study demonstrates that Perioperative Nivolumab plus chemotherapy is a viable and safe option for systemically treating locally advanced resectable OSCC, and monitoring minimal residual disease through ctDNA could be potentially valuable for assessing the effectiveness of adjuvant therapy and for prognostic evaluation in a systemic manner. Presented study results on non-small cell lung cancer and gastrointestinal stromal tumor (GIST) at the ASCO in June 2025. 'Personalized tumor-informed ctDNA has the potential to inform recurrence in high-risk locally advanced stage GIST patients, especially for patients with irregular adjuvant therapy' and 'MUSETALK-Lung01 (MUltiomics SEquencing Technique AppLication Kick-start) is a prospective, longitudinal, observational study designed to evaluate the clinical utility of a tumor-naïve ctDNA assay in patients with early-stage non-small cell lung cancer (NSCLC).' Presented multiple study results at the 2025 AACR in April, showcasing the clinical utility of the tumor-informed personalized MRD assay (CanCatch® Custom) and the tumor-naïve methylation-based MRD assay. First Quarter 2025 Financial Results Revenues were RMB133.1 million (US$18.3 million) for the three months ended March 31, 2025, representing a 5.9% increase from RMB125.6 million for the same period in 2024. Revenue generated from central laboratory business was RMB38.3 million (US$5.3 million) for the three months ended March 31, 2025, representing a 19.6% decrease from RMB47.6 million for the same period in 2024, primarily attributable to a decrease in the number of tests, as we continued to focus on our in-hospital business. Revenue generated from in-hospital business was RMB57.7 million (US$7.9 million) for the three months ended March 31, 2025, representing a 0.5% increase from RMB57.4 million for the same period in 2024, driven by a continuous growth in sales volume. Revenue generated from pharma research and development services was RMB37.1 million (US$5.1 million) for the three months ended March 31, 2025, representing a 79.9% increase from RMB20.6 million for the same period in 2024, primarily attributable to increased development and testing services performed for our pharma customers, and several milestones of our pharma programs were achieved. Cost of revenues was RMB35.7 million (US$4.9 million) for the three months ended March 31, 2025, representing a 10.6% decrease from RMB39.9 million for the same period in 2024, primarily due to a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business. Gross profit was RMB97.4 million (US$13.4 million) for the three months ended March 31, 2025, representing a 13.7% increase from RMB85.7 million for the same period in 2024. Gross margin was 73.2% for the three months ended March 31, 2025, compared to 68.2% for the same period in 2024. By channel, gross margin of central laboratory business was 84.1% for the three months ended March 31, 2025, compared to 77.7% during the same period in 2024, primarily due to a reduction in material and labor costs resulted from cost optimization and control measures and a decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarter; gross margin of in-hospital business was 76.1% for the three months ended March 31, 2025, compared to 68.3% during the same period in 2024, primarily due to the same reason; gross margin of pharma research and development services was 57.5% for the three months ended March 31, 2025, compared to 46.1% during the same period of 2024, primarily due to the cost optimization measures and an increase in test volume of higher margin projects. Non-GAAP gross profit, which excludes depreciation and amortization expenses, RMB100.7 million (US$13.9 million) for the three months ended March 31, 2025, representing an 8.3% increase from RMB93.0 million for the same period in 2024. Non-GAAP gross margin was 75.6% for the three months ended March 31, 2025, compared to 74.0% for the same period in 2024. Operating expenses were RMB112.6 million (US$15.5 million) for the three months ended March 31, 2025, representing a 46.8% decrease from RMB211.5 million for the same period in 2024. The decrease was primarily driven by budget control measures and headcount reduction to improve the Company's operating efficiency. Research and development expenses were RMB40.4 million (US$5.6 million) for the three months ended March 31, 2025, representing a 38.8% decrease from RMB66.0 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in the expenditure for detection research and (iii) a decrease in depreciation and amortization. Selling and marketing expenses were RMB40.9 million (US$5.6 million) for the three months ended March 31, 2025, representing a 12.7% decrease from RMB46.9 million for the same period in 2024, primarily due to (i) a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency and (ii) a decrease in depreciation and amortization. General and administrative expenses were RMB31.3 million (US$4.3 million) for the three months ended March 31, 2025, representing a 68.3% decrease from RMB98.7 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in depreciation and amortization; (iii) a decrease in staff cost resulted from the reorganization; and (iv) a decrease in operating lease expense for office building. Net loss was RMB13.5 million (US$1.9 million) for the three months ended March 31, 2025, compared to RMB121.5 million for the same period in 2024. Cash, cash equivalents and restricted cash were RMB497.4 million (US$68.5 million) as of March 31, 2025. Exchange Rate Information This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: Safe Harbor Statement This press release contains forward-looking statements. These statements constitute 'forward-looking' statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'target,' 'confident' and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Non-GAAP Measures In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ('U.S. GAAP'). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization. The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company's ongoing business operations in a manner that allows more meaningful period-to-period comparisons. Contact: IR@ Selected Operating Data As of March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 In-hospital Channel: Pipeline partner hospitals(1) 28 29 30 29 30 Contracted partner hospitals(2) 59 59 61 63 63 Total number of partner hospitals 87 88 91 92 93(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company's products. (2) Refers to hospitals that have entered into contracts to purchase the Company's products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals. Selected Financial Data For the three months ended Revenues March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 (RMB in thousands) Central laboratory channel 47,614 48,773 39,984 39,278 38,296 In-hospital channel 57,387 59,872 63,769 43,464 57,687 Pharma research and development channel 20,622 26,888 24,891 43,280 37,099 Total revenues 125,623 135,533 128,644 126,022 133,082 For the three months ended Gross profit March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 For the three months ended Share-based compensation expenses March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Cost of revenues 596 464 289 520 308 Research and development expenses 12,287 12,008 3,180 3,202 1,800 Selling and marketing expenses 508 1,232 1,917 1,353 1,025 General and administrative expenses 55,990 54,407 4,732 2,937 1,413 Total share-based compensation expenses 69,381 68,111 10,118 8,012 4,546 Burning Rock Biotech Limited Unaudited Condensed Statements of Comprehensive Loss (in thousands, except for number of shares and per share data) For the three months ended March 31,2024 June 30,2024 September 30, 2024 December 31,2024 March 31, 2025 March 31, 2025 RMB RMB RMB RMB RMB US$ Revenues 125,623 135,533 128,644 126,022 133,082 18,340 Cost of revenues (39,929 ) (40,095 ) (36,798 ) (36,600 ) (35,681 ) (4,918 ) Gross profit 85,694 95,438 91,846 89,422 97,401 13,422 Operating expenses: Research and development expenses (65,985 ) (64,952 ) (49,150 ) (52,203 ) (40,389 ) (5,566 ) Selling and marketing expenses (46,856 ) (48,907 ) (48,411 ) (46,730 ) (40,888 ) (5,635 ) General and administrative expenses (98,681 ) (92,794 ) (32,874 ) (37,289 ) (31,303 ) (4,314 ) Impairment loss on long-lived assets (35,127 ) Total operating expenses (211,522 ) (206,653 ) (130,435 ) (171,349 ) (112,580 ) (15,515 ) Loss from operations (125,828 ) (111,215 ) (38,589 ) (81,927 ) (15,179 ) (2,093 ) Interest income 4,038 3,187 3,173 1,814 2,581 356 Other income (expense), net 434 (82 ) 1 4,353 (652 ) (90 ) Foreign exchange (loss) gain, net (13 ) 262 (129 ) (220 ) (26 ) (4 ) Loss before income tax (121,369 ) (107,848 ) (35,544 ) (75,980 ) (13,276 ) (1,831 ) Income tax expenses (180 ) (190 ) (201 ) (5,314 ) (224 ) (31 ) Net loss (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to Burning Rock Biotech Limited's shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to ordinary shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Loss per share for class A and class B ordinary shares: Class A ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Class B ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Weighted average shares outstanding used in loss per share computation: Class A ordinary shares - basic and diluted 85,219,188 85,271,858 85,902,670 86,036,286 90,291,658 90,291,658 Class B ordinary shares - basic and diluted 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 Other comprehensive income (loss), net of tax of nil: Foreign currency translation adjustments 590 940 (4,054 ) 6,009 (72 ) (10 ) Total comprehensive loss (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands) As of December 31, 2024 March 31,2025 March 31,2025 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 519,849 495,145 68,233 Restricted cash 2,313 2,261 312 Accounts receivable, net 152,013 159,463 21,974 Contract assets, net 13,855 17,178 2,367 Inventories, net 62,625 65,424 9,016 Prepayments and other current assets, net 25,963 22,072 3,042 Total current assets 776,618 761,543 104,944 Non-current assets: Property and equipment, net 47,152 41,162 5,672 Operating right-of-use assets 53,188 43,804 6,036 Intangible assets, net 421 386 53 Other non-current assets 7,926 7,822 1,078 Total non-current assets 108,687 93,174 12,839 TOTAL ASSETS 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands) As of December 31,2024 March 31,2025 March 31,2025 RMB RMB US$ LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable 33,747 35,938 4,952 Deferred revenue 117,895 117,200 16,151 Accrued liabilities and other current liabilities 89,498 76,198 10,501 Customer deposits 592 592 82 Current portion of operating lease liabilities 24,567 22,524 3,104 Total current liabilities 266,299 252,452 34,790 Non-current liabilities: Non-current portion of operating lease liabilities 27,754 19,814 2,730 Other non-current liabilities 10,425 10,649 1,467 Total non-current liabilities 38,179 30,463 4,197 TOTAL LIABILITIES 304,478 282,915 38,987 Shareholders' equity: Class A ordinary shares 124 124 17 Class B ordinary shares 21 21 3 Additional paid-in capital 5,002,255 5,005,991 689,844 Treasury stock (63,264 ) (62,453 ) (8,606 ) Accumulated deficits (4,200,261 ) (4,213,761 ) (580,672 ) Accumulated other comprehensive loss (158,048 ) (158,120 ) (21,790 ) Total shareholders' equity 580,827 571,802 78,796 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands) For the three months ended March 31,2024 March 31,2025 March 31,2025 RMB RMB US$ Net cash generated from (used in) operating activities 19,062 (23,527 ) (3,242 ) Net cash used in investing activities (812 ) (1,531 ) (211 ) Net cash used in financing activities (74 ) - - Effect of exchange rate on cash, cash equivalents and restricted cash 5,739 302 43 Net increase in (decrease) cash, cash equivalents and restricted cash 23,915 (24,756 ) (3,410 ) Cash, cash equivalents and restricted cash at the beginning of period 498,247 522,162 71,955 Cash, cash equivalents and restricted cash at the end of period 522,162 497,406 68,545 Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results For the three months ended March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Gross profit: Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 Add: depreciation and amortization: Central laboratory channel 1,919 1,226 1,277 1,010 562 In-hospital channel 1,524 824 798 623 290 Pharma research and development channel 3,856 4,417 3,846 2,534 2,412 Total depreciation and amortization included in cost of revenues 7,299 6,467 5,921 4,167 3,264 Non-GAAP gross profit： Central laboratory channel 38,921 39,650 34,539 34,163 32,753 In-hospital channel 40,716 44,882 47,378 30,186 44,185 Pharma research and development channel 13,356 17,373 15,850 29,240 23,727 Total non-GAAP gross profit 92,993 101,905 97,767 93,589 100,665 Non-GAAP gross margin： Central laboratory channel 81.7% 81.3% 86.4% 87.0% 85.5% In-hospital channel 70.9% 75.0% 74.3% 69.5% 76.6% Pharma research and development channel 64.8% 64.6% 63.7% 67.6% 64.0% Total non-GAAP gross margin 74.0% 75.2% 76.0% 74.3% 75.6%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Wall Street Legend Bets Against Strategy -- Says Bitcoin Investors Are Paying Double
Jim Chanos (Trades, Portfolio) is backwith a trade that's turning heads. The famed short-seller behind the Enron call is now targeting Strategy (NASDAQ:MSTR), not for its crypto exposure, but because of it. On a recent podcast, Chanos laid out what he believes is one of the cleanest arbitrage setups he's seen in years: short MSTR, long Bitcoin (BTC-USD). His reasoning? At current prices, buying the stock is like paying $220,000 for Bitcoin that trades near $110,000. That's because MicroStrategy's share price still reflects a steep premium over the company's actual Bitcoin holdings, even after the spread has started to narrow. Warning! GuruFocus has detected 8 Warning Signs with MSTR. It's not just Chanos. Hedge funds have been circling this trade since MicroStrategy transformed itself into a kind of Bitcoin-holding company. Fueled by Michael Saylor's capital-raising spree, the firm has used equity and convertible debt to amass billions in BTC. Retail investors followed, helping push the stock far beyond its net asset value. While some bulls argue that leverage and zero-fee exposure justify the premium, skeptics are betting that rising dilution and tighter spreads will eventually bring the valuation back to earth. According to Bloomberg data, when factoring in dilution and stripping out the firm's legacy software business, MSTR is still trading at nearly double the value of its underlying crypto assets. Not everyone is jumping in. Firms like Kerrisdale promoted the trade in early 2024 but have since stepped away, citing timing challenges. TD Cowen analyst Lance Vitanza, meanwhile, believes the premium might persistthanks to Bitcoin-per-share growth and MicroStrategy's unique structure. For now, the short side is cheap to maintain, with borrow costs still low and liquidity deep. But risks remain: unexpected corporate shifts, volatile BTC moves, or changes in short dynamics could all shake up the math. Chanos remains focused on the long game, saying the spread could compress meaningfully over timebut even he acknowledges this one's better suited for hedge funds than personal portfolios. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
